Haru MORITA
President and Chief Executive Officer
Mr. Morita has served as President, Chief Executive Officer and Director of REGiMMUNE since March 2006. Prior to REGiMMUNE, Mr. Morita was the managing director of Think-n-Go Corporation, a privately held consulting firm providing corporate strategy, portfolio management and business development services. Previously Mr. Morita served on the management teams of Y's Therapeutics, Ltd. and Y's Therapeutics, Inc., most recently as Director of Business Development, where he was responsible for directing the company's business development and corporate planning activities. Mr. Morita's professional experience also includes strategic consulting positions at Booz Allen and Hamilton (Tokyo office). Prior to that, Mr. Morita worked as a research scientist in the medical research group at Kirin Brewery Co. Ltd. At Kirin he was part of the research and development team that was first to clone Megakaryocyte Growth and Differentiation Factor (MDGF or Thrombopoietin). He received both a BS in Chemical Engineering and an MS in Molecular and Cellular Biology from the University of Tokyo.

Teikichi AOYAGI, Ph.D.
Senior Vice President, Chief Development Officer
Dr. Aoyagi joined REGiMMUNE in July 2006 from Y's Therapeutics, Ltd., where he was Senior Vice President and Chief Operating Officer. Previously, he worked in several divisions of Roche including Head of Roche Alliance Group at Chugai Roche, Head of Strategic Planning at Nippon Roche and Global Project Team Leader for early-stage projects at Roche. Prior to Roche, Dr. Aoyagi was Director of Product Development at Genentech Limited; and he gained broad drug development experience in various therapeutic areas at Amgen, Marion Merrill Dow, Servier and Meiji Seika Kaisha, Ltd. He received both his MS and Ph.D. degrees from the University of Osaka.
　
　
Reiko NAMIKAWA, M.D., Ph.D
Senior Vice President, Development and Strategy
Dr. Namikawa brings more than 25 years of research, clinical and business experience in lifesciences to REGiMMUNE. Most recently, Dr. Namikawa supported strategic planning, business development and venture capital financing as a business consultant for clients including ProtElix, Inc., where she served as the company’s chief scientific advisor and Abmaxis, which was acquired by Merck in May 2006. Among her many accomplishments, Dr. Namikawa was a founding scientist at SyStemix, Inc. where she developed the SCID-hu mouse system for the company, which she invented at Stanford University with two colleagues. Dr. Namikawa also held senior positions at Clearview Projects, Inc. and DNAX Research Institute as well as GeneTrol Biotherapeutics, Inc. and BioGenomics, Inc. She received both her Ph.D. in Pathology and her M.D. from Nagoya University School of Medicine; and completed postdoctoral training at Stanford in Dr. Irving Weissman’s lab.